Tisotumab vedotin is a tissue factor (TF)-directed ADC consisting of an anti-TF monoclonal antibody conjugated to MMAE via a cleavable linker, with a DAR of 4, and received FDA approval for treating adult patients with recurrent or metastatic cervical cancer in April 2024 (Administration FaD, 2025). This evidence concerns the gene TF and cervical cancer.